Psych Diagnoses Fraud Leads to Pharmaceutical Prosecutions

NowPublic.com
Kevin Hall
October 8, 2012

Nearly all major psychiatric drug manufacturers have been convicted of illegal marketing and/or fraudulent claims. Several of these cases are linked below. Any that haven't been prosecuted, probably should be.

The reason behind this is simple. There are no medical tests to confirm or deny any mental disorder or diagnoses. A few decades back, psychiatrists "voted" that mental "illness" was caused by a "chemical imbalance of the brain." This is drug marketing, not science. Nobody votes in diabetes or cancer as medical disease and there are sound medical and lab tests for these and other medical diseases.

Psychiatric diagnoses is merely opinion of behavior. Psychiatrists simply vote on what is or is not a mental disorder and place these diagnoses into the American Psychiatric Association's "Diagnostic and Statistical Manual." Their controversial DSM5 is set to be released in 2013 and will likely lead to more pharmaceutical fraudulent marketing prosecutions and settlements.

The reason is simple. If there is no identifiable disease, there can never be a drug that will cure. In fact, there are no cures for any mental disorders. The drugs are generally uppers (ADHD drugs) or downers (anti-anxiety drugs and antipsychotics) that merely mask symptoms in some cases while having extremely dangerous side effects. The upper-type antidepressants have been proven to be very little, if any, more effective than a placebo (sugar pill) yet greatly increase sexual dysfunction while also increasing the likelihood of violence and suicide. Honest marketing would refer to them as anti-sex drugs.

The flow (explained and graphed here) is that psychiatrists create a disease by voting, then pharmaceuticals make the drug. Psychiatrists, usually at major universities, create fraudulent studies that the FDA approves on the word of the drug companies that funded the studies. Once they get approval for a certain condition (such as depression) and population (such as men over age 18, etc.), they get some paid-off psychiatrist to create and get published a study saying that the drug is helpful for other populations and diagnoses. This allows for what is termed off-label prescribing.

It's all fraud and all prosecutable.

The story printed below on Abbott Labs (Depakote) came out last week. It's the Virginia Attorney General's press release www.oag.state.va.us/Media%20and%20News%20Releases/News_Releases/Cuccinelli/100212_Abbott_Labs.html .
Here are some other links to recent settlements with:

GlaxoSmithKline (Paxil) http://www.justice.gov/opa/pr/2012/July/12-civ-842.html ;

Johnson & Johnson, (Risperdal, Invega) www.nytimes.com/2012/04/12/business/drug-giant-is-fined-1-2-billion-in-arkansas.html?_r=0, www.bloomberg.com/news/2012-08-30/j-j-will-pay-181-million-to-settle-risperdal-ad-claims.html, http://www.bloomberg.com/news/2012-08-31/j-j-loses-appeal-of-257-7-million-risperdal-verdict.html  ;

Pfizer, (Zoloft,Geodon, etc.) www.msnbc.msn.com/id/32657347/ns/business-us_business/t/pfizer-pay-record-billion-penalty/#.UHLjXVF_P1U ;

Astrazeneca, (Seroquel) www.azcentral.com/business/articles/2010/04/27/20100427astra-zeneca-settlement.html ;

Bristol-Myers Squibb (Abilify) www.justice.gov/opa/pr/2007/September/07_civ_782.html ;

Eli Lilly (Zyprexa) www.justice.gov/opa/pr/2009/January/09-civ-038.html .

Maybe it is time that some of the psychiatrists creating the fraudulent diagnoses and studies start getting criminally prosecuted for fraud?


Commonwealth of Virginia
Office of the Attorney General


For media inquiries only, contact:  Brian J. Gottstein
Email: bgottstein@oag.state.va.us (best contact method)
Phone: 804-786-5874

Sentencing in Abbott Labs Depakote case: Judge approves $1.5 billion settlement to resolve complaints of off-label promotion of drug

~ Virginia-led investigation was largest state Medicaid fraud investigation in U.S. history ~

ABINGDON, VA (October 2, 2012) - As part of the largest Medicaid fraud case ever led by a state, Attorney General Ken Cuccinelli announced the sentencing of global health care company Abbott Laboratories Inc. in the United States District Court in Abingdon, Va., today. The court approved the $1.5 billion settlement reached on May 7, 2012, among Abbott, Virginia, the United States government, and 48 other states and the District of Columbia, in which Abbott pled guilty to a criminal charge and admitted civil liability for the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration (FDA). 

The attorney general's Medicaid Fraud Control Unit (MFCU) was the lead investigative agency in the case, partnering with the prosecutors and civil attorneys from the U.S. Attorney's Office for the Western District of Virginia. This was the largest Medicaid fraud recovery in U.S. history resulting from a state-led investigation, with the Virginia MFCU spending more than four years on the investigation, traveling to 26 states to conduct interviews and sifting through more than one million records looking for evidence.

When it pled guilty in May, Abbott agreed to pay $1.5 billion to resolve its criminal and civil liability pertaining to government health care programs that were defrauded based on reimbursements paid for Depakote due to Abbott's illegal marketing practices. The settlement that was approved today includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. The civil settlement includes $270 million for the federal government's share of the Medicaid program; $239 million for the states' share of the Medicaid program; and $291 million for Medicare and other federal programs. Abbott will also pay a $500 million fine to the federal government, $198.5 million in criminal asset forfeiture penalties, and $1.5 million to Virginia MFCU to cover investigative costs. Virginia's share of the Medicaid civil settlement is $4.2 million. 

Abbott must also agree to the terms of a Corporate Integrity Agreement with the Office of the Inspector General for the Department of Health and Human Services.

"I've made fighting Medicaid fraud a priority in Virginia by increasing the size of our fraud team by adding 30 new people over the last two years," said Cuccinelli. "I'm committed to ensuring that money intended for medical services for the poor isn't stolen from them and the taxpayers through fraud. Medicaid dollars are limited, and fraud deprives people in true need of necessary medical care."

He continued, "This settlement will allow 49 states, the District of Columbia, and the federal government to recover money fraudulently taken from Medicaid, Medicare, and other health care programs." Louisiana is pursuing separate litigation.

On May 7, Abbott pled guilty to misbranding Depakote by promoting the drug to control agitation and aggression in elderly dementia patients and to treat schizophrenia when neither of these uses was FDA approved. In an agreed statement of facts filed in the criminal action, Abbott admitted that from 1998 through 2006, the company maintained a specialized sales force trained to market Depakote in nursing homes for the control of agitation and aggression in elderly dementia patients, despite the absence of credible scientific evidence that Depakote was safe and effective for that use. In addition, from 2001 through 2006, the company marketed Depakote in combination with atypical antipsychotic drugs to treat schizophrenia, even after its clinical trials failed to demonstrate that adding Depakote was any more effective than an atypical antipsychotic alone for that use.

The FDA is responsible for approving drugs as safe and effective for specified uses. Under the Food, Drug and Cosmetic Act (FDCA), a company in its application to the FDA must specify each intended use of a drug. A company's promotional activities must be limited to only the intended uses that are FDA approved. Promotion by the manufacturer for other uses - known as "off-label" uses - renders the product misbranded, and is illegal.

 For more information on the history of the Abbott Labs settlement, please click here.

Virginia's role in the Abbott case

In September 2007, the Virginia attorney general's Medicaid Fraud Control Unit (MFCU) was contacted with allegations of off-label drug marketing by Abbott Pharmaceuticals.

Although neither the whistleblowers nor the defendant in this case were located in Virginia, the whistleblowers came to Virginia because the MFCU has a national reputation for successfully investigating major national cases, such as the Purdue Pharma Oxycontin case, the Octagon case, and others.

Following Virginia MFCU's initial investigation, the unit contacted the U.S. Attorney's Office for the Western District of Virginia because of their history of working together on such cases. They then began a joint investigation.

On October 31, 2007, the first qui tam ("whistleblower") suit was filed in the United States District Court in Abingdon, Va., against Abbott Laboratories for marketing the drug Depakote for off-label uses. Three other qui tam complaints from other relators were subsequently filed.

MFCU investigators operating out of the attorney general's offices in Roanoke and Abingdon were assigned to the investigation full-time and spent more than four years and 38,000 man-hours on the investigation, traveling to 26 states to conduct interviews and sifting through more than one million records looking for evidence.

The investigation uncovered that Abbott illegally marketed Depakote for non-approved uses, including as an alternative to antipsychotics to treat dementia patients in nursing homes, and for schizophrenia. The investigation also revealed that Abbott paid rebates to health care professionals and long-term care pharmacies for increasing their off-label use of Depakote. 

Attorney General Cuccinelli would like to thank Randall "Randy" Clouse, Director and Chief of Health Care Fraud and Elder Abuse section, and the following MFCU investigators and attorneys for their work in this case: Erica Bailey, Mary Blackburn, Steve Buck, Beverly Darby, Harold Erwin, Elizabeth Fitzgerald, William Clay Garrett, Doug Johnson, John Johnston, Kristy Knighton, Adele Neiburg, John Peirce, and Joey Rusek.

Virginia's MFCU: A history of stopping Medicaid fraud

The Virginia MFCU was established in 1982 within the attorney general's office to investigate and prosecute insurance fraud against the federally funded Medicaid program for indigent health services. MFCU employs a professional staff of criminal investigators, auditors, and several assistant attorneys general who are experienced in commercial and financial investigations. MFCU works regularly with federal and state law enforcement agencies, as well as private insurance companies operating within Virginia.

Over the past 30 years, prior to the Abbott case, Virginia's MFCU had recovered nearly $800 million by tracking down and prosecuting Medicaid fraud offenders. This fiscal year alone, MFCU has recovered more than $22 million. MFCU was also involved in the recovery of more than $634 million after a joint criminal investigation revealed that Purdue Pharma Company fraudulently misbranded the drug OxyContin by marketing the drug to physicians as a slower release -- and thus less addictive -- drug than other prescription opioids. 

From 2010 to today, Attorney General Cuccinelli increased the number of Medicaid fraud and elder abuse staff by more than 50 percent (from 56 to 86) to better combat fraud in Virginia's Medicaid program and to protect the elderly from individuals who abuse and neglect them in nursing homes and health care facilities. It is the only section of the office that he has grown significantly during his tenure, while he has maintained a smaller general fund budget allocation than when he came into office.

Rebecca Riley's doctor on the defense

The Patriot Ledger
by Lane Lambert
Apr 10, 2010

BOSTON — Years before she became a board-certified psychiatrist, Dr. Kayoko Kifuji was diagnosing children as young as 2 as bipolar and hyperactive – and prescribing powerful cocktails of mood-altering drugs to quiet them.

By the time Kifuji finally passed the psychiatric board exam – on her fourth try – one of her youngest patients, Rebecca Riley, had a little more than a year to live. Her parents murdered the 4-year-old by overdosing her with one of the drugs Kifuji prescribed.

Both of Rebecca’s parents are in prison for her murder. Her mother, Carolyn, was convicted in February; her father, Michael, in March.

Now the spotlight is on the controversial doctor who testified in both trials in exchange for immunity. Kifuji and her employer, Tufts Medical Center, face a malpractice lawsuit filed by Norwell attorney Brian Clerkin, the court-appointed administrator for Rebecca’s estate, which was created for the benefit Rebecca’s brother and sister, who are now 14 and 9.

Glimpses into Kifuji’s background and treatment methods are part of a lengthy deposition she gave in December in the civil suit. The final pretrial hearing in the case is scheduled for June 1.

Kifuji diagnosed Rebecca Riley and her sister with mental illness and prescribed drugs for both girls and their brother. Prosecutors in the parents’ murder trials said the Rileys killed Rebecca because they couldn’t get disability payments for her, as they had with their two other kids.

According to the plaintiff’s lawyer in the malpractice suit, Benjamin P. Novotny, of the Boston firm Lubin and Meyer, Kifuji said she “trusted the mother” (Carolyn Riley) to tell her how the children were behaving and reacting to the drugs. She relied almost exclusively on what Carolyn told her about the kids when diagnosing them and ordering increasing amounts of drugs for them.

Kifuji also trusted the mother to keep tabs on Rebecca’s heart rate and blood pressure for signs of problems with the four drugs she was on. Kifuji, a pediatrician who later became a psychiatrist, told Novotny during the deposition that she didn’t realize she had a blood pressure cuff in her office and could check the girl’s vital signs herself until after Rebecca was dead. She said she didn’t take Rebecca’s pulse with her fingers because Carolyn Riley told her the child’s pulse “was within normal range.”

Kifuji also told Novotny during the deposition:

She prescribed clonidine – the drug that killed Rebecca – during the child’s first visit to control the “impulsivity” that Carolyn Riley described. Rebecca was 2 at the time.

She originally came to the United States from her native Japan in 1990 to research dust allergies in children. She switched her training to psychiatry when she went to New England Medical Center in 1994.

In 2000, she took a job at Baystate Medical Services in Springfield because it meant she wouldn’t have to return to Japan for two years and wait for an H-1 work visa.

She diagnosed dozens of children as bipolar or having attention deficit hyperactivity disorder (ADHD) or both, and estimated that she prescribed drugs for 99 percent of her pediatric patients.

She usually saw Rebecca for 20 minutes at each office visit because she was seeing all three Riley children in an hour.

She explained that some researchers believe the area of the brain called the amygdala is different in people with bipolar disease. But she admitted she didn’t know where the amygdala is in the brain.

Kifuji’s medical career has taken her from Tokyo to Detroit and Boston. She was living in Somerville as of December.

She grew up in Kumamoto, Japan, on the southwest tip of the island of Kyushu, and graduated from Tokyo Women’s Medical College in 1981.

She’s been a permanent legal resident of the U.S. since 1990, and has held a medical license here since 1999.

She worked at Baystate in Springfield from 2000-03. Her outpatients there included the Rileys’ two older children, whom she also diagnosed as bipolar with ADHD.

After Rebecca’s death in December 2006, Tufts Medical Center placed Kifuji on paid leave after the psychiatrist agreed not to practice medicine. The state Board of Registration in Medicine reinstated her license this past September after Plymouth County District Attorney Timothy Cruz announced that a grand jury would not bring criminal charges against her.

In January, Tufts reaffirmed its support for Kifuji and her treatment methods, saying she provided “appropriate” care to Rebecca Riley. Kifuji began seeing patients again in the fall. As of December, she was seeing five outpatients – four children and one adult – and working with a state-funded child psychiatric access program.

Lane Lambert is at llambert@ledger.com.




Kifuji’s treatment of Rebecca Riley

2004

Aug. 27, 2004: Carolyn Riley takes her daughter Rebecca to Kifuji for the first time. Within 20 minutes of meeting the then 2-year-old, she Kifuji diagnoses her with attention deficit hyperactivity disorder and prescribes clonidine as a sedative.

Sept. 1, 2004: Carolyn tells Kifuji over the phone that she has increased Rebecca’s clonidine dosage. Kifuji approves.

Oct. 1, 2004: Second office visit lasts 20 minutes.

Nov. 9, 2004: Refills clonidine prescription.

Dec. 9, 2004: Refills clonidine prescription.

2005


Jan. 3, 2005: Kifuji increases clonidine dosage over the phone.

Jan. 5, 2005: Third office visit. Kifuji reports Rebecca’s hyperactivity has worsened from mild to moderate. Increases clonidine dosage for the third time.

March 11, 2005: Carolyn tells Kifuji over the phone that Rebecca is having “lots of headaches,” a common side effect of clonidine.

May 3, 2005: Diagnoses 3-year-old Rebecca with bipolar disorder after mother tells her the girl has become “moody” and cries “over very small things easily.” Prescribes Depakote, an antiseizure drug.

June, July, August 2005: Refills prescriptions for clonidine and Depakote.

Aug. 4 and Aug. 31, 2005: Sees Rebecca in the office. No changes in diagnoses or dosage.

Oct. 27, 2005: Carolyn tells Kifuji she has increased Rebecca’s clonidine dosage again.
Kifuji tells her to decrease it and threatens to report Carolyn to the state. Kifuji increases Depakote dosage and prescribes Zyprexa, an antipsychotic.

Nov. 162005: Increases Depakote dosage.

December2005: Increases Zyprexa dosage.



2006



Jan. 9, 2006: Increases Zyprexa dosage again. Writes, “Present dose working well. No changes.”

Jan. 31, 2006: Increases Depakote dosage again after Carolyn reports that 3-year-old Rebecca is wetting the bed.

Feb. 16:, 2006 Prescribes Seroquel, an antipsychotic. Decreases Zyprexa. Notes Rebecca is gaining “too much weight and she’s still very aggressive and impatient.”

March 8, 2006: Increases Depakote dosage. Carolyn reports Rebecca is still having problems sleeping, is defiant and having tantrums.

May 24, 2006: Receives letter from a social worker concerned about the amount of drugs being given to the Riley children.

June 22, 2006: Increases Rebecca’s Seroquel dosage after 20-minute office visit.

July 20, 2006: Increases Depakote dosage after mother reports Rebecca was “getting into everything.”

Aug. 16, 2006: Tells Carolyn Riley she can increase or decrease drug dosages on her own. Changes clonidine prescriptions to 10-day supplies instead of month’s supply after Carolyn Riley says the last prescription was destroyed by water.

Aug. 21, 2006: Pharmacist tells Kifuji over the phone that Carolyn came in for pills but didn’t have doctor’s authorization. Kifuji gives it over the phone. Riley cannot explain 20 missing clonidine pills.

Sept. 15, 2006: Increases Rebecca’s Seroquel dosage again, the 13th drug increase she’s approved in two years. Tells mother that she can increase it even more.

Nov. 3, 2006: Returns call from the nurse at Rebecca’s preschool in Weymouth who says the 4-year-old is like a “floppy doll” and is so tired she can barely walk up the stairs. Nurse says she is concerned about how much medication Rebecca is on.

Nov. 10, 2006: Kifuji notes that mother says Rebecca’s sleep is improved and attributes it to Michael Riley having moved back in with the family at their new apartment in Hull.
Dec. 7, 2006: Sees Rebecca for the last time. Tells mother she’ll begin decreasing clonidine dosage if Rebecca continues to do well.

Dec. 13, 2006: Rebecca dies of clonidine overdose. Kifuji calls the Rileys and leaves a message for Carolyn.

Dec. 14, 2006: Carolyn calls Kifuji at 6:45 a.m. and leaves a message. Kufuji calls back at 4:45 p.m., 5:15 p.m., 6 p.m., 6:30 p.m. and at 7:20 p.m. when she reaches Carolyn. Kufiji says she called to ask what happened to Rebecca and see how Carolyn is doing.



Defending Dr. Kifuji



John P. Ryan, the lawyer for Dr. Kayoko Kifuji in the medical malpractice suit filed against her by Rebecca Riley’s estate, re cently talked to The Patriot Ledger about the case. Here is some of what he said: Here are some of the questions and answers from the interview:

Q: How do the issues in the civil case compare to those in the criminal cases against Rebecca’s parents?
A: “The issues in the criminal trials were narrowed by the nature of the claims in those cases, and the full expla nation of the medicines (pre scribed by Dr. Kifuji) will be developed in the civil case. It is unfortunate and ironic in the light of the convictions in the criminal trials that there has been an unwarranted displace ment of blame onto Dr. Kifuji.”

Q: Was Dr. Kifuji too quick or willing to prescribe drugs for a child so young?
A:“The medical records will disclose that Dr. Kifuji had numerous visits with the child (Rebecca Riley), and had the opportunity to personally view and assess the child and follow a treatment regime that is recognized and accepted in the complex field of pediatric psy chiatry. Dr. Kifuji is board-certified in pediatrics, general psychiatry and child and adolescent psychiatry. She is both academically trained and very experienced in her field. We expect in the civil case that competent and qualified expert opinion will both explain and support her treatment of this child.”

Q: Was it acceptable practice for Kifuji to approve an increase in the dosage of clonidine after Carolyn Riley told her (over the phone) that she had already started giving Rebecca more of the drug than originally prescribed?
A: “Her decision-making was based not only on observations from the mother, but from Dr. Ki fuji’s personal observations and experience in the field.”

Q: What’s your response to the harsh criticism of Kifuji from both prosecutors and defense attorneys during the Riley trials?
A: “The civil action is the proceeding in which Dr. Kifuji has the opportunity to present her affirmative side of the case, with appropriate expert analysis.”

Q: When will the civil trial begin?
A: “We are still probably as much as a year away from the trial on the civil case.”



Troubled toddler or drug-seeking mom?

Dr. Kayoko Kifuji diagnosed then 2-year-old Rebecca Riley with attention deficit hyperactivity disorder after Kifuji’s first 20-minute visit with the child in 2004. That’s when she first prescribed clonidine, the drug that killed Rebecca in 2006. Kifuji had already diagnosed Rebecca’s sister with ADHD and bipolar disorder and prescribed many of the same drugs for her and their brother.

Here are some of Kifuji’s treatment notes on Rebecca, which are in a deposition Kifuji gave in December in a pending medical malpractice suit:

* A week before her first appointment with Rebecca, Kifuji wrote: “Called mother. Two years old. Very hyper. All over. Last couple of week, not sleeping but keep going like her brother who was not sleeping when he was small.”
* Kifuji described Rebecca during the first office visit:

“Two-and-half-year-old female with history of colic and not sleeping much in her infancy developed sleep disturbance again. Hyperactivity on and off since four months ago. Then consistently hyper all the time. Climbs up to top of jungle gym without any fears and thinking. Gets into everything. Just walk up to someone and smack them. Never gets aggressive. Hits kicks and spits when she’s being disciplined and laughs. Started to say things scared her. Whines and fusses a lot.”

* During the same visit when Rebecca was 21/2 years old, Kifuji described the toddler as dysarthric, meaning she could not properly pronounce some words. She also described Rebecca as a “happy” child with a “bright affect.”

* During her second 20-minute visit with Rebecca, in October 2004, Kufuji wrote: “Doing okay. A bit tired since yesterday. Coming down on flu. Fine as long as she takes clonidine. Sleeps throughout. Without clonidine gets very hyper and impulsive.”

She also wrote: “(Rebecca) is loud and silly at times while she was playing with her sister but redirectable.”

* During later visits, Kifuji described Rebecca as “very impulsive.” She explained that Rebecca’s mother said the girl: “Climbs up on top of bureau. Tantrums or sobbing when she was told to clean up her toys” and “she wasn’t listening to her mother.” Rebecca was 3.

* Three months after diagnosing Rebecca as bipolar, Kifuji noted that the family is under increased stress because Michael Riley has been accused of sexually abusing a girl. She writes of Rebecca: “Gets aggressive to her sibs with hitting and kicking. Can’t go out to play with kids in neighborhood due to the allegations, and they had pressure to move out from (Weymouth).”

* Asked why she didn’t report Carolyn Riley to child welfare authorities after learning that the mother had increased the children’s doses at least twice without checking with her first, Kifuji said: “I just can’t report to the DSS. I need to ... my role is to work with the parent and not judging them.”

* Asked if she ever told Carolyn not to give Rebecca cold medicine on top of all the drugs the child was on, Kifuji says no, “but it’s because Rebecca didn’t get sick, and I was never asked ...”



Kifuji’s medical career

1981: Graduates from Tokyo Women’s Medical College in Japan.

May 1981-April 1983: Resident in pediatrics at Toyko Women’s Medical College.

May 1983-April 1987: Fellow in pediatric allergy at Toyko Women’s Medical College.

Feb. 1991-June 1994: Researcher on dust allergies in children at Henry Ford Hospital in Detroit.

1994-1999: Resident in pediatrics/psychiatry/child psychiatry at New England Medical Center, Boston.

June 1999: Receives Massachusetts medical license.

October 1999: Board-certified in pediatrics.

February 2000-July 2003: Worked at Baystate Medical Services in Springfield.

August 2003: Began job at Tufts Medical Center, Boston.

October 2005: Board-certified in general psychiatry.

November 2006: Board-certified in adolescent psychiatry.

February 2007: Agrees not to practice following the death of Rebecca Riley.

July 2009: A Plymouth County grand jury decides not to return an indictment against Kifuji, clearing her of criminal charges in Rebecca’s death.

September 2009: Returns to practice after state Board of Registration in Medicine reinstates her medical license.


Copyright 2010 The Patriot Ledger. Some rights reserved
==================================================================

---Comments (12)---


How the hell can ANYONE tell if a 2 year old is bipolar?

'She explained that some researchers believe the area of the brain called the amygdala is different in people with bipolar disease. But she admitted she didnt know where the amygdala is in the brain.'


I doubt this quack could find her ass with both hands with a cowbell duct taped to it. And the board gave her license back?
rcamom
2 days ago

when my children were small, it was called the 'terrible two's'. That poor baby. The doctor should lose her license to prescribe medication.
MyChristmas
2 days ago

Its time for the state to step in and go through this so called doctors files and review EVERY case that involves children she prescribed meds to. She is most certainly a danger to children and an embarassment to the medical profession.
I'm going to say this for my 1st time as a poster here on the ledger 'DEPORT HER'
DannyHaszard

Zyprexa,as well as the other atypical antipsychotics, are being prescribed for children, even though this is an unapproved, off-label use.

A report by Dr. Cooper at Vanderbilt University states that 2.5 million children are now taking atypical antipsychotics. Over half are being given them for Attention Deficit Hyperactivity Disorder. Perhaps it is statistics like these that caused the FDA to finally require warnings on the labels of the ADHD drugs.

The use of atypical antipsychotics for children should be banned.
--

Daniel Haszard www.zyprexa-victims.com
jenjambam
2 days ago

I was told my daughter was ADHA in third grade. I don't give a **** what the school said, took her to her pediatrician she did not agree. School advised to get a dianosis whether or not I wanted meds, which they were not recommending, just so she could get some benefits when it came to test times.Took her to a phyc Dr. to get diagnosis, she said yup but just slite case, no recommendation for meds. Thank God, I could care less if she bounces of the wall while doing home work as long as it get done. And it does, just takes a bit longer than others. Worth every minutie to have her alive.
nemesis
2 days ago

Two year-olds, I find hard to believe , are 'bi-polar'.....they are just 'two year-olds, acting like two year-olds......This Doctor (choke) should have her license revoked.
DannyHaszard
2 days ago

Eli Lilly has made 40 billion on 10 dollar a pill Zyprexa and it was way oversold and caused diabetes and in some cases sudden death. Zyprexa was pushed by Lilly Drug Reps.

They called it the 'Five at Five' (5 mg at 5 pm to keep nursing home patients subdued and sleepy) and 'VIVA ZYPREXA' (Zyprexa for everybody) campaigns to off label market Eli Lilly Zyprexa as a fix for unapproved usage.I am a living example of Zyprexa gone/done wrong was given it 1996-2000 off-label for PTSD got sudden high blood sugar A1C 14.7 in January 2000.The stuff was worthless for my condition PTSD and cost me thousands in co-pays gave me diabetes.

--

Daniel Haszard
Oscar Wood
2 days ago

The question still has to be asked does the doctor speak English well enough to undersatnd what is going on? She is another immigrant. Remember she passed her bards on the 4th try. That's right the fourth try. Any decent person would have quit and joined the pharmaceutical industry, the dumping ground of not quite so bright medical minds. it is a disgrace that she is able to see patients. Oscar
Fiend4Mojitos
2 days ago

Didn't know there was a BP Cuff in her office?
Does she know what a BP Cuff looks like?
sisyphus
2 days ago

Tufts Medical Center and the state board of registration for medicine should be ashamed for reinstating this horrible person who somehow managed to get a medical degree. Kudos to the reporters at the Ledger who gathered all this information. I am glad they are keeping this issue in the news.
21 hours ago

She's as guilty as guilty does....poorly trained and not too bright. I don't trust foreign born medical practioner's in general and even less so those involved in the psychiatric profession. They have caused much harm to young and old. May God help her she is hellbound!
kimnjulia
17 hours ago

Today (April 11) would have been Rebeccas 8th birthday. Kifuji may have been granted immunity here - but heaven help her. Karmas organic and on duty too.